DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cozaar (Losartan Potassium) - Summary

 
 



USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, COZAAR should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

 

COZAAR SUMMARY

What is the most important information I should know about COZAAR?

COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist.

COZAAR is indicated for the following:

Hypertension

COZAAR is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics.

Hypertensive Patients with Left Ventricular Hypertrophy

COZAAR is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See PRECAUTIONS, Race and CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Reduction in the Risk of Stroke, Race.)

Nephropathy in Type 2 Diabetic Patients

COZAAR is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio >/=300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, COZAAR reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects).


See all Cozaar indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Cozaar (Losartan)

AHA: Losartan Disappoints in Hypertrophic Cardiomyopathy (CME/CE)
Source: MedPage Today Cardiovascular [2014.11.20]
(MedPage Today) -- ARB no better than placebo for reducing left ventricular hypertrophy.

Atenolol vs Losartan in Patients With Marfan Syndrome
Source: theheart.org | Medscape Cardiology Headlines [2014.11.18]
Drs Bowen and Connolly discuss the results of a landmark head-to-head comparison of losartan vs atenolol in patients with Marfan syndrome.
Mayo Clinic

more news >>

Published Studies Related to Cozaar (Losartan)

Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study. [2012]
once-daily combination amlodipine/losartan versus losartan... CONCLUSION: Switching to a fixed-dose combination therapy of amlodipine/losartan

Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. [2012]
Korean patients with mild-to-moderate hypertension... CONCLUSIONS: In this study with eligible adult Korean patients who had

Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension. [2012]
insulin-resistant subjects... CONCLUSIONS: These findings argue against the hypothesis that losartan might

Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. [2011.11]
The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension...

Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. [2011.08]
BACKGROUND: No prospective, randomized, double-blind trials of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have previously been reported in adults or children with proteinuria secondary to Alport syndrome... CONCLUSIONS: Losartan significantly lowered proteinuria and was well tolerated after 12 weeks of treatment in children aged 1-17 years with proteinuria secondary to Alport syndrome with or without hypertension, a population that has not previously been rigorously studied.

more studies >>

Clinical Trials Related to Cozaar (Losartan)

Losartan Therapy in Pulmonary Hypertension [Completed]
In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration of endothelial dysfunction. These beneficial effects, render those agents appropriate for use in the treatment of pulmonary hypertension. However, data regarding the use of ACEIs or ARBs in the treatment of PHT are limited. In this study, efficacy of an ARB, losartan was compared with those of the calcium channel blocker, nifedipine in the treatment of pulmonary hypertension using echocardiographic, 6-minute walk test (6MWT), cardiopulmonary exercise test, and endothelin-1 levels. Losartan is as effective as nifedipine for reducing Doppler echocardiographically measured PAP and improving exercise capacity on 6MWT and CPET. However the short-term use of losartan or nifedipine had no statistically significant effect on endothelin-1 levels in patients with PHT.

An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension [Terminated]
Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.

A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension [Terminated]
The purpose of this study is to test the safety and effectiveness of Losartan as compared to Losartan/HCTZ in pediatric patients (6 to 17 years) with high blood pressure.

A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan [Recruiting]
Study Design :

- A single center, open, randomized, single dose, two-period, two-treatment,

two-sequence, crossover study

Primary Objective:

- To assess the bioequivalence of combination oral formulation of amlodipine/losartan

versus two co-administered products containing amlodipine and losartan

Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly [Not yet recruiting]
The general hypothesis is that elderly have diminished nutritive flow to skeletal muscle and impaired capacity for building of muscles. In aging populations, this decreased ability to build muscles may represent a tipping point in the progression towards chronic physical frailty and disability. The goal is to examine whether novel pharmacologic therapies can improve nutritive blood flow to the muscles and muscle building in the elderly.

The purpose of this study is 1) to determine if losartan administration will enhance the building of muscles via proteins and suppress muscle breakdown 2) to determine if N-acetylcysteine (NAC) will enhance blood flow to muscles and the building of muscles via proteins.

The investigators will study community dwelling, healthy older men and women (60-85 years). Subjects will be randomized to one of three groups:

Experimental Group 1: Placebo losartan and placebo N-acetylcysteine (NAC). Experimental Group 2: losartan (25mg/dose) and placebo N-acetylcysteine (NAC). Experimental Group 3: N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo

Subjects will admit the night before and get their first dose of NAC/ losartan/ placebo with dinner. Subjects will be fasted after 10 pm. The next morning at 6 am blood samples will be taken and leg blood flow (LBF) will be measured. Subjects will receive their second dose of NAC/ losartan/ placebo. As from 6 am every hour blood will be drawn until 1 pm. At 8am, the second biopsy is taken and LFB and CEU will be measured. At 11am they get their third dose of NAC/ losartan/ placebo together with leucine (oral) and again a muscle biopsy is taken and LBF is measured. Leucine is anabolic to skeletal muscle of elderly and so the investigators will use it to stimulate muscle building.

more trials >>

Reports of Suspected Cozaar (Losartan) Side Effects

Dizziness (20)Pain (19)Blood Pressure Increased (19)Asthenia (19)Somnolence (18)Nausea (18)Anaemia (18)Malaise (16)Feeling Abnormal (14)Confusional State (13)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 4 ratings/reviews, Cozaar has an overall score of 9.25. The effectiveness score is 9.50 and the side effect score is 9.50. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
 

Cozaar review by 56 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   high blood pressure
Dosage & duration:   50 mg taken one time a day for the period of over 9 years
Other conditions:   Crohn's disease
Other drugs taken:   Boniva
  
Reported Results
Benefits:   Within a few weeks of starting, my pressure was under control and has remained that way for over 5 years.
Side effects:   I had no side effects that I noticed.
Comments:   I was diagnosed with high blood pressure (145/90) over 10 years ago, a few years after experiencing early menopause. Severe headaches were also commmon. First treatment: dietary changes and increasing daily exercise--not adequate; in fact, it increased. I was prescribed Cozaar, 50 mg/day, with the reminder that the first dosage tried was rarely the correct one. In my case, it was and I get checked now every 6 months. My blood pressure stays around 118/70 range.

 

Cozaar review by 67 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   Blood Pressure
Dosage & duration:   50 MG taken once a day for the period of 3 Months
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   Did lower my blood pressure after about 3 weeks. Remained lower during remainder of course and after the treatment ended.
Side effects:   No significant side-effects in my experience. Some mild diarrhea at the beginning of the course, nothing really after the first couple of days.
Comments:   Once a day for three months to treat high blood pressure.

 

Cozaar review by 67 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   Blood Pressure
Dosage & duration:   50 MG taken once a day for the period of 3 Months
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   Did lower my blood pressure after about 3 weeks. Remained lower during remainder of course and after the treatment ended.
Side effects:   No significant side-effects in my experience. Some mild diarrhea at the beginning of the course, nothing really after the first couple of days.
Comments:   Once a day for three months to treat high blood pressure.

See all Cozaar reviews / ratings >>

Page last updated: 2014-11-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014